

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/575,114
Confirmation Number	9365
Filing Date	April 10, 2006
First Named Inventor	Shigeru IIDA
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	Q105982

## U.S. PATENTS

Examiner Initials*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

## U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number <sup>2</sup>	Country Code <sup>3</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T <sup>5</sup>
	1	XP002355427: SHINKAWA T ET AL: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody - dependent cellular cytotoxicity" Journal of Biological Chemistry, American Society For Biochemistry and Molecular Biology, Birmingham, US, Vol. 278, no. 5, January 31, 2003, pages 3466-3473	
	2	XP002442140: SHIELDS ROBERT L ET AL: Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody - dependent cellular toxicity" JOURNAL OF BIOLOGICAL CHEMISTRY, American Society For Biochemistry and Molecular Biology, BIRMINGHAM, US, Vol. 277, No. 30, July 26, 2002, pages 26733-26740	
	3	XP000941446: NAKAMURA K ET AL: " CHIMERIC ANTI-GANGLIOSIDE GM2 ANTIBODY WITH ANTITUMOR ACTIVITY" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, Vol. 54, No. 6 March 15, 1994, pages 1511-1516	
	4	XP002944543: NAKAMURA KAZUYASU ET AL: " Apoptosis induction of the human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody" CANCER RESEARCH, Vol. 59, No. 20, October 15, 1999, pages 5323-5330	

## EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.